fluconazole has been researched along with AIRE Deficiency in 6 studies
Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.
fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fluconazole resistance was detected in isolates from one patient, and isolates exhibiting a progressive reduction in itraconazole and/or fluconazole susceptibility were identified in a further 3/16 patients, in each case correlating with the upregulation of CDR- and MDR-encoded efflux pumps." | 1.37 | Microbiological screening of Irish patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy reveals persistence of Candida albicans strains, gradual reduction in susceptibility to azoles, and incidences of clinical signs of oral candid ( Coleman, DC; Costigan, C; Fleming, P; Healy, CM; McGovern, E; McManus, BA; Moran, GP; Nunn, J; Sullivan, DJ, 2011) |
| "albicans (n = 19) isolates from nine APECED patients reported with decreased susceptibility to fluconazole isolated up to 9 years apart were included." | 1.36 | Persistent Candida albicans colonization and molecular mechanisms of azole resistance in autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) patients. ( Bowyer, P; Rautemaa, R; Richardson, M; Sanglard, D; Saxen, H; Siikala, E, 2010) |
"albicans from 23 APECED patients isolated during the years 1994 to 2004 were divided into 2 groups: fluconazole-susceptible dose-dependent (MIC, 16-32 microg/mL, 18 isolates) and fluconazole-susceptible (MIC | 1.35 | Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis ( Perheentupa, J; Pfaller, MA; Rautemaa, R; Richardson, M; Saxén, H, 2008) | |
| " Our data indicate that discretion should be used in the long-term use of all azoles, including topical miconazole." | 1.35 | Reduction of fluconazole susceptibility of Candida albicans in APECED patients due to long-term use of ketoconazole and miconazole. ( Perheentupa, J; Pfaller, M; Rautemaa, R; Richardson, M; Saxen, H, 2008) |
| "Fluconazole was effective in all three cases." | 1.30 | [Familial chronic mucocutaneous candidiasis associated with autoimmune polyendocrinopathy. Treatment with fluconazole: 3 cases]. ( Abimelec, P; Bourrat, E; Feuilhade, M; Morel, P; Rybojad, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Humbert, L | 1 |
| Cornu, M | 1 |
| Proust-Lemoine, E | 1 |
| Bayry, J | 1 |
| Wemeau, JL | 1 |
| Vantyghem, MC | 1 |
| Sendid, B | 1 |
| Rautemaa, R | 3 |
| Richardson, M | 3 |
| Pfaller, MA | 1 |
| Perheentupa, J | 2 |
| Saxén, H | 3 |
| Pfaller, M | 1 |
| Siikala, E | 1 |
| Bowyer, P | 1 |
| Sanglard, D | 1 |
| McManus, BA | 1 |
| McGovern, E | 1 |
| Moran, GP | 1 |
| Healy, CM | 1 |
| Nunn, J | 1 |
| Fleming, P | 1 |
| Costigan, C | 1 |
| Sullivan, DJ | 1 |
| Coleman, DC | 1 |
| Rybojad, M | 1 |
| Abimelec, P | 1 |
| Feuilhade, M | 1 |
| Morel, P | 1 |
| Bourrat, E | 1 |
1 review available for fluconazole and AIRE Deficiency
| Article | Year |
|---|---|
Chronic Mucocutaneous Candidiasis in Autoimmune Polyendocrine Syndrome Type 1.
Topics: Adrenal Insufficiency; AIRE Protein; Animals; Autoantibodies; Candida albicans; Candidiasis, Chronic | 2018 |
5 other studies available for fluconazole and AIRE Deficiency